Evidence map›Paper›PMID 30097508›Full record

Trial reportBlood2018

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.

Nigel Russell, Alan Burnett, Robert Hills, Sophie Betteridge, Mike Dennis, Jelena Jovanovic, Richard Dillon, David Grimwade, NCRI AML Working Group

Abstract readClinical TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nigel RussellCentre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
Alan BurnettDepartment of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom.
Robert HillsCentre for Trials Research, Cardiff University, Cardiff, United Kingdom.
Sophie BetteridgeCentre for Trials Research, Cardiff University, Cardiff, United Kingdom.
Mike DennisHaematology and Transplant Unit, The Christie, Manchester, United Kingdom; and.
Jelena JovanovicDepartment of Medical and Molecular Genetics, King's College Medical School, London, United Kingdom.
Richard DillonDepartment of Medical and Molecular Genetics, King's College Medical School, London, United Kingdom.
David GrimwadeDepartment of Medical and Molecular Genetics, King's College Medical School, London, United Kingdom.
NCRI AML Working Group

Funding

Cancer Research UK 13371Cancer Research UK 16484
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsArsenic TrioxideFemaleFollow-Up StudiesHumansLeukemia, Promyelocytic, AcuteMaleMiddle AgedNeoplasm Recurrence, LocalSurvival AnalysisTretinoinYoung AdultAntineoplastic AgentsArsenic TrioxideTretinoin

Identifiers

PMID30097508
PMCPMC6225356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.